AUROBINDO PHARMA Financial Statement Analysis
|
||
The Revenues of AUROBINDO PHARMA have increased by 5.97% YoY .
The Earnings Per Share (EPS) of AUROBINDO PHARMA has decreased by -27.21 % YoY. |
REVENUES |
OPERATING MARGIN |
PROFIT AFTER TAX |
EPS |
ROCE |
AUROBINDO PHARMA Last 5 Annual Financial Results
[BOM: 524804|NSE : AUROPHARMA]
Consolidated | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
---|---|---|---|---|---|
Revenues | ₹24,855 Cr | ₹23,455 Cr | ₹24,775 Cr | ₹23,099 Cr | ₹19,564 Cr |
Expenses | ₹21,137 Cr | ₹19,071 Cr | ₹19,441 Cr | ₹18,234 Cr | ₹15,612 Cr |
Operating Profit (Excl OI) | ₹3,719 Cr | ₹4,385 Cr | ₹5,333 Cr | ₹4,864 Cr | ₹3,952 Cr |
Other Income | ₹291 Cr | ₹323 Cr | ₹381 Cr | ₹192 Cr | ₹155 Cr |
Interest | ₹140 Cr | ₹49 Cr | ₹74 Cr | ₹305 Cr | ₹263 Cr |
Depreciation | ₹1,245 Cr | ₹1,127 Cr | ₹1,055 Cr | ₹967 Cr | ₹668 Cr |
Profit Before Tax | ₹2,613 Cr | ₹3,373 Cr | ₹7,344 Cr | ₹3,743 Cr | ₹3,089 Cr |
Profit After Tax | ₹1,928 Cr | ₹2,647 Cr | ₹5,334 Cr | ₹2,844 Cr | ₹2,362 Cr |
Consolidated Net Profit | ₹1,928 Cr | ₹2,648 Cr | ₹5,335 Cr | ₹2,845 Cr | ₹2,365 Cr |
Earnings Per Share (Rs) | ₹32.90 | ₹45.20 | ₹91.05 | ₹48.56 | ₹40.36 |
PAT Margin (%) | 3.79 | 5.54 | 10.98 | 6.02 | 5.89 |
ROE(%) | 7.50 | 11.38 | 27.53 | 18.52 | 18.47 |
ROCE(%) | 9.39 | 12.71 | 30.10 | 18.72 | 17.97 |
Total Debt/Equity(x) | 0.18 | 0.10 | 0.23 | 0.33 | 0.50 |
Key Financials |
||
Market Cap | : | ₹ 59,612.4 Cr |
Revenue (TTM) | : | ₹ 27,894.7 Cr |
Net Profit(TTM) | : | ₹ 2,777.9 Cr |
EPS (TTM) | : | ₹ 47.4 |
P/E (TTM) | : | 21.5 |
Industry Peers & Returns | 1W | 1M | 1Y |
AUROBINDO PHARMA | -2.6% | -1.6% | 122.3% |
SUN PHARMACEUTICAL INDUSTRIES | -0.8% | 4% | 61.6% |
DIVIS LABORATORIES | -2.1% | -6% | 26.4% |
CIPLA | 1.5% | 3.3% | 70.6% |
DR REDDYS LABORATORIES | 0.7% | 0.4% | 44.6% |
TORRENT PHARMACEUTICALS | -4% | -2.8% | 70.3% |
ABBOTT INDIA | 6% | -3% | 39.7% |
ZYDUS LIFESCIENCES | 0.3% | 11.1% | 109.1% |
ALKEM LABORATORIES | -1.5% | -8.6% | 63.1% |
AUROBINDO PHARMA Revenues
[BOM: 524804|NSE : AUROPHARMA]
Y-o-Y | 5.97 % |
5 Yr CAGR | 6.17 % |
Years | Revenues | % Change | |
---|---|---|---|
Mar2023 | ₹24,855 Cr | 5.97 | |
Mar2022 | ₹23,455 Cr | -5.32 | |
Mar2021 | ₹24,775 Cr | 7.26 | |
Mar2020 | ₹23,099 Cr | 18.07 | |
Mar2019 | ₹19,564 Cr | - |
AUROBINDO PHARMA Operating Profit
[BOM: 524804|NSE : AUROPHARMA]
Y-o-Y | -15.19 % |
5 Yr CAGR | -1.51 % |
Years | Operating Profit | % Change | |
---|---|---|---|
Mar2023 | ₹3,719 Cr | -15.19 | |
Mar2022 | ₹4,385 Cr | -17.79 | |
Mar2021 | ₹5,333 Cr | 9.64 | |
Mar2020 | ₹4,864 Cr | 23.09 | |
Mar2019 | ₹3,952 Cr | - |
Operating Margins | |
---|---|
Y-o-Y | -19.96 % |
5 Yr CAGR | -7.23 % |
Years | Operating Margin% | % Change | |
---|---|---|---|
Mar2023 | 14.96% | -19.96 | |
Mar2022 | 18.69% | -13.19 | |
Mar2021 | 21.53% | 2.23 | |
Mar2020 | 21.06% | 4.26 | |
Mar2019 | 20.2% | - |
AUROBINDO PHARMA Profit After Tax
[BOM: 524804|NSE : AUROPHARMA]
Y-o-Y | -27.21 % |
5 Yr CAGR | -4.98 % |
Years | Profit After Tax | % Change | |
---|---|---|---|
Mar2023 | ₹1,928 Cr | -27.21 | |
Mar2022 | ₹2,648 Cr | -50.36 | |
Mar2021 | ₹5,335 Cr | 87.51 | |
Mar2020 | ₹2,845 Cr | 20.32 | |
Mar2019 | ₹2,365 Cr | - |
PAT Margins | |
---|---|
Y-o-Y | -31.59 % |
5 Yr CAGR | -10.44 % |
Years | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2023 | 3.79 % | -31.59 | |
Mar2022 | 5.54 % | -49.54 | |
Mar2021 | 10.98 % | 82.39 | |
Mar2020 | 6.02 % | 2.21 | |
Mar2019 | 5.89 % | - |
AUROBINDO PHARMA Earnings Per Share (EPS)
[BOM: 524804|NSE : AUROPHARMA]
Y-o-Y | -27.21 % |
5 Yr CAGR | -4.98 % |
Years | EPS | % Change | |
---|---|---|---|
Mar2023 | ₹33 | -27.21 | |
Mar2022 | ₹45 | -50.36 | |
Mar2021 | ₹91 | 87.50 | |
Mar2020 | ₹49 | 20.32 | |
Mar2019 | ₹40 | - |
AUROBINDO PHARMA Return on Capital Employed (ROCE)
[BOM: 524804|NSE : AUROPHARMA]
Y-o-Y | -26.12 % |
5 Yr CAGR | -14.98 % |
Years | ROCE | % Change | |
---|---|---|---|
Mar2023 | 9.39% | -26.12 | |
Mar2022 | 12.71% | -57.77 | |
Mar2021 | 30.1% | 60.79 | |
Mar2020 | 18.72% | 4.17 | |
Mar2019 | 17.97% | - |
AUROBINDO PHARMA Share Price vs Sensex
Current Share Price | : | ₹1,017.5 |
Current MarketCap | : | ₹ 59,612.4 Cr |
Updated EOD on | : | Mar 18,2024 |
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
AUROBINDO PHARMA | -2.6% |
-1.6% |
122.3% |
SENSEX | -1% |
1% |
24.9% |
AUROBINDO PHARMA related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE LARGE MIDCAP | -1.9% | -0.1% | 35.5% |
S&P BSE 200 | -1.9% | -0.1% | 35.3% |
S&P BSE 250 LARGEMIDCAP | -2% | -0.4% | 35.3% |
S&P BSE HEALTHCARE | -2.1% | -2.4% | 59.2% |
S&P BSE 500 | -2.2% | -0.9% | 36.5% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY PHARMA | -2% | 1.3% | 62.2% |
NIFTY 200 | -2% | -0.3% | 35.5% |
NIFTY HEALTHCARE | -2.1% | -1% | 59.4% |
NIFTY 500 | -2.2% | -1% | 37.3% |
NIFTY LARGE MIDCAP 250 | -2.7% | -1.8% | 41.9% |
You may also like the below Video Courses
FAQ about AUROBINDO PHARMA Financials
How the annual revenues of AUROBINDO PHARMA have changed ?
The Revenues of AUROBINDO PHARMA have increased by 5.97% YoY .
How the Earnings per Share (EPS) of AUROBINDO PHARMA have changed?
The Earnings Per Share (EPS) of AUROBINDO PHARMA has decreased by -27.21 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
DR REDDYS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD vs